Примери за използване на This referral procedure на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Efficacy was not assessed in this referral procedure.
This referral procedure concerns the products in UK, AT and DE.
Efficacy was not assessed in this referral procedure.
Thus the outcome of this referral procedure does not include any evaluation of the gel formulation.
However, the efficacy assessment does not fall within the scope of this referral procedure.
This referral procedure did not cover other fentanyl formulations such as tablets, nasal sprays or solutions for injection.
Dementia and dementia related indications are excluded from the scope of this referral procedure.
Some of the products included in the scope of this referral procedure are indicated for use in foals.
The harmonisation of the quality module was requested by the MAH at the beginning of this Referral procedure.
The basis for this referral procedure was a harmonisation of the summary of product characteristics, labelling and package leaflet.
No further risk management ormitigation measures are required as a consequence of this referral procedure.
The Applicant/ MAH proposed to take the Ciprofloxacin Modified Release Tablets out of this Referral procedure to significantly simplify the exercise of harmonisation.
Dementia and dementia related indications,as well as the acute treatment of migraine, are outside the scope of this referral procedure.
The CHMP therefore recommended the suspension of the marketing authorisations for all remaining medicinal products concerned by this referral procedure, as bioequivalence vis-à-vis the EU reference medicinal products has not been demonstrated.
However, there are some significant differences between this andthe other product formulations that are in the scope of this referral procedure.
Some of them were conducted with the intravenous administration which is not in the scope of this referral procedure for dihydroergotamine.
Each MAH of HES solutions for infusion shall perform a drug utilisation study to assess the effectiveness of the risk minimisation measures implemented as an outcome of this referral procedure.
The warning on cardiomyopathy andmyocarditis was included through a type II variation, which was finalised during the assessment of this referral procedure under Article 30 from Directive 2001/83/EC started.
Two reports in support of the claimed indication in the treatment of irritable bowel syndrome(IBS)were submitted in the context of this referral procedure.
The Committee concluded that the data is considered to have a limited value for the scope of this referral procedure.
Pigs were already authorised as a target species for all products concerned by this referral procedure.
The study reports were significantly re-worked by the MAH for review during this referral procedure.
Quality, target animal safety, user safety andresidues were not assessed in this referral procedure.
The quality and safety(apart from target animal safety)of Fiprex were not assessed in this referral procedure.
Quality, target animal safety, user safety, environmental risk andresidues were not assessed in this referral procedure.
Quality, Target animal safety, User safety, Residues, Resistance andEfficacy were not assessed in this referral procedure.
Quality, target animal safety, user safety, consumer safety andefficacy were not assessed in this referral procedure.
The results of those studies should be provided to the relevant Authorities for assessment not later than 18 months after the Commission Decision on this referral procedure.
The reasons for these observations are not known and cannot be determined from this study, noron basis of other data presented during this referral procedure.
The variation in posology amongst the nationally authorised Summary of Product Characteristics(SPC)meant that this issue also needed to be addressed in this referral procedure.